Skip to Main Content

A pair of Democratic lawmakers is asking the Food and Drug Administration to provide documents that would explain its decision last fall to approve Dsuvia, a tablet version of a decades-old intravenous painkiller that is up to 10 times more potent than the highly addictive fentanyl.

The agency greenlighted its use amid controversy that alternatives exist and that such a powerful opioid could easily be abused by being diverted, despite a prohibition on retail pharmacy sales. But as noted previously, the endorsement was championed by the military, which maintained that such a medicine is needed in combat zones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!